Brief: Genmab Gets FDA Breakthrough Therapy Designation For Rinatabart Sesutecan

Genmab A/S

26/08/2025 13:05

Aug 26 (Reuters) - Genmab A/S GMAB.CO:

GENMAB RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR RINATABART SESUTECAN (RINA-S®) IN ADVANCED ENDOMETRIAL CANCER (EC)

RINA-S CONTINUES TO BE EVALUATED AS A SINGLE-AGENT IN PATIENTS WITH ADVANCED EC IN PHASE 1/2 RAINFOL™-01 TRIAL AND WILL BE FURTHER EVALUATED IN A PLANNED PHASE 3 TRIAL

Source text: ID:nGNE4tWzCk

Further company coverage: GMAB.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))